更新于：2024-12-16
Leucovorin Calcium
亚叶酸钙
更新于：2024-12-16
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1952-06-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C20H23CaN7O7 |
InChIKeyBZPWXVJDMRBCMD-ZEDZUCNESA-N |
CAS号1492-18-8 |
关联
1,006
项与 亚叶酸钙 相关的临床试验A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
A First-in-human, Open-label, Dose Escalation, Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies in Patients With Advanced Solid Tumors
Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination With FOLFOX Plus Bevacizumab as Frontline Treatment in Patients With Metastatic Colorectal Cancer
100 项与 亚叶酸钙 相关的临床结果
登录后查看更多信息
100 项与 亚叶酸钙 相关的转化医学
登录后查看更多信息
100 项与 亚叶酸钙 相关的专利（医药）
登录后查看更多信息
5,529
项与 亚叶酸钙 相关的文献（医药）2025-01-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Reverse engineering of Onivyde® – Irinotecan liposome injection
Article
作者: Juang, Vivian ; Wang, Yan ; Zheng, Jiwen ; Xu, Xiaoming ; Lin, Winnie ; Ackermann, Rose ; Xia, Ziyun ; Yu, Minzhi ; Park, Jin H ; Liang, Jing ; Schwendeman, Anna ; Wang, Xinye ; Wang, Kaikai ; Gan, Jingyao ; Dorsey, Kristen Hong
Onivyde® is an intravenous irinotecan liposomal injection approved by the FDA for the treatment of gemcitabine-refractory metastatic adenocarcinoma of the pancreas in combination with fluorouracil and leucovorin. In the Onivyde® formulation, irinotecan is encapsulated in the inner compartment of the liposome using sucrose octasulfate as a trapping agent, and stabilized by a pegylated lipid membrane, resulting in prolonged circulation in the body. Due to its complex formulation design, there is limited information available regarding the critical quality attributes (CQAs) of Onivyde® and suitable methods for evaluating these attributes. In this study, we have developed a series of analytical methods to comprehensively characterize Onivyde®. These methods encompass particle size analysis, morphology and structure assessment, examination of physical and chemical properties, determination of drug and lipid contents, and evaluation of its release behavior in vitro.
2025-01-01EUROPEAN JOURNAL OF CANCER
Patient access to perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel in patients with resectable gastric cancer in the Netherlands
Article
作者: Nieuwenhuijzen, Grard A P ; Pape, Marieke ; van Hellemond, Irene E G ; Wijnhoven, Bas P L ; Rosman, Camiel ; Mostert, Bianca ; Verhoeven, Rob H A ; van Laarhoven, Hanneke W M ; Vissers, Pauline A J ; Geerts, Julie F M
BACKGROUND:
The FLOT4 trial demonstrated superior survival of perioperative chemotherapy with 5-fluorouracil, oxaliplatin, and docetaxel (FLOT) compared to anthracycline triplets for resectable gastric cancer. These results were presented at the American Society of Clinical Oncology (ASCO) congress in June 2017 and published in April 2019. However, adoption of novel treatments in clinical practice often encounters delays. This study assesses the patterns of perioperative chemotherapy utilization and FLOT uptake in clinical practice within the Netherlands.
MATERIALS AND METHODS:
A retrospective cohort study was conducted with resectable gastric cancer patients (cT1-4a,XcNallcM0) between 2015-2020 from the Netherlands Cancer Registry. Descriptive statistics, Cochran-Armitage tests, Fisher's exact or unpaired T-tests, and Jonckheere-Terpstra tests were used to analyze chemotherapy trends and FLOT uptake across hospitals.
RESULTS:
Among 3290 included patients, 42.9 % received neoadjuvant treatment. In 2015, 43.6 % of patients received perioperative chemotherapy versus 43.5 % in 2020 (p = 0.63). 40 out of 62 hospitals (64.5 %) adopted FLOT between the ASCO presentation and the full publication. FLOT increased from 42.9 % before publication to 86.8 % after publication (p < 0.0001), while anthracycline triplet use decreased to 0.9 % (p < 0.0001). Higher hospital volume was associated with fewer days to adoption (p = 0.04) but not with adoption of FLOT before publication (p = 0.14).
CONCLUSION:
Timing of FLOT adoption varied among Dutch hospitals, leading to unequal patient access to effective treatments. Establishing (inter)national guidelines on provisional treatment adjustment pending publication is crucial to reduce variation in access. Moreover, rapid publication of final trial results is imperative to reduce variation in practice and ensure fair patient treatment.
2024-12-15INTERNATIONAL JOURNAL OF CANCER
A multicenter, prospective, phase II trial of second‐line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti‐EGFR antibody: HGCSG1801
Article
作者: Dazai, Masayoshi ; Yoshikawa, Ayumu ; Yuki, Satoshi ; Muranaka, Tetsuhito ; Sogabe, Susumu ; Sakata, Yu ; Kotaka, Masahito ; Takagi, Ryo ; Sagawa, Tamotsu ; Kawamoto, Yasuyuki ; Ando, Takayuki ; Nakamura, Michio ; Harada, Kazuaki ; Hatanaka, Kazuteru ; Sasaki, Yusuke ; Tateyama, Miki ; Komatsu, Yoshito ; Nakatsumi, Hiroshi ; Sawada, Kentaro ; Muto, Osamu ; Ishiguro, Atsushi
Abstract:
Aflibercept (AFL) plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer (mCRC). However, there is limited evidence on the efficacy and safety of AFL plus FOLFIRI previously treated with anti‐epidermal growth factor receptor (EGFR) agents. Therefore, we conducted a prospective open‐label phase II trial evaluating the efficacy and safety of AFL plus FOLFIRI in Japanese patients with mCRC failing a prior oxaliplatin‐based chemotherapy plus an anti‐EGFR agent. AFL (4 mg/kg iv) followed by FOLFIRI (irinotecan 180 mg/m2, leucovorin 200 mg/m2 iv, bolus 5‐fluorouracil [5‐FU] 400 mg/m2, and infusional 5‐FU 2400 mg/m2/46 h) was given every 2 weeks until progression or unacceptable toxicities. The primary endpoint was progression‐free survival (PFS) rate at 6 months. Forty three patients were enrolled between November 2019 and October 2022. The primary endpoint was met: 6‐month PFS rate was 58.8% (90% confidence interval [CI], 45.7%–72.0%). Median PFS and OS were 7.3 months (95% CI, 5.5–11.0 months) and 18.8 months (95% CI, 12.9–26.6 months), respectively. The overall response rate was 20.9% (95% CI, 10.0–36.0%) and disease control rate was 88.4% (95% CI, 74.9–96.1%). The main grade ≥3 adverse events included hypertension (62.8%), neutropenia (55.8%), leukopenia (25.6%), febrile neutropenia (11.6%), fatigue (9.3%), anorexia (9.3%), proteinuria (9.3%), and diarrhea (7.0%). No deaths and no new safety signals with a causal relation to the study treatment were observed. This study suggests that AFL plus FOLFIRI shows a high response rate and a manageable safety profile in Japanese patients with mCRC who failed prior oxaliplatin‐based chemotherapy plus an anti‐EGFR agent.
100 项与 亚叶酸钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 结直肠癌 | 日本 | 2003-07-17 | |
| 结直肠癌 | 日本 | 2003-07-17 | |
| 药物中毒 | 日本 | 1963-01-11 | |
| 贫血 | 美国 | 1952-06-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性结直肠癌 | 临床3期 | 美国 | 1999-11-01 | |
| 晚期胃癌 | 临床2期 | 中国 | 2011-07-01 | |
| 复发转移性胃癌 | 临床2期 | 中国 | 2011-07-01 | |
| 直肠癌 | 临床1期 | 美国 | 2014-06-01 | |
| 复发性结肠癌 | 临床1期 | 美国 | 2014-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 45 | 範築壓願觸鹹壓鹹鑰願(願鏇積顧願繭膚選襯遞) = 鏇鹹襯醖範齋餘選憲襯 壓鬱鏇壓築鏇繭鹹觸齋 (願襯構醖壓鑰膚醖夢觸, 選顧蓋願網膚選鏇襯獵 ~ 窪選構夢窪蓋憲鏇餘窪) 更多 | - | 2024-09-23 | |||
临床2期 | 19 | Stereotactic Body Radiation+Leucovorin Calcium+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL (Cohort 1: SBRT and FOLFIRINOX) | 範憲膚鑰夢範簾廠醖壓(齋鏇夢憲衊憲繭簾網築) = 鹽簾艱繭繭醖選簾鏇範 壓鹽顧網範製窪鬱鹹鏇 (糧獵艱餘蓋簾衊觸範鬱, 壓範願繭鏇齋夢醖觸築 ~ 選糧遞蓋鏇積製淵繭淵) 更多 | - | 2024-08-14 | ||
Stereotactic Body Radiation (Cohort 2: SBRT and Modified FOLFIRINOX) | 範憲膚鑰夢範簾廠醖壓(齋鏇夢憲衊憲繭簾網築) = 糧觸鹹繭顧齋鑰願蓋襯 壓鹽顧網範製窪鬱鹹鏇 (糧獵艱餘蓋簾衊觸範鬱, 淵淵壓鑰選選壓獵醖積 ~ 淵夢繭遞鬱窪淵窪夢顧) 更多 | ||||||
临床2期 | 117 | LV5FU2 (Aflibercept + LV5FU2) | 衊夢鬱衊醖觸積憲顧齋(鏇夢鏇糧糧窪襯鹹襯廠) = 網衊糧醖築廠餘築衊糧 繭遞襯鹽構築築膚壓簾 (壓艱壓遞鑰觸鬱廠鏇顧, 夢顧遞積遞繭壓憲選糧 ~ 觸鏇繭憲構顧鬱願餘淵) 更多 | - | 2024-07-10 | ||
LV5FU2+folinic acid+5FU (LV5FU2) | 衊夢鬱衊醖觸積憲顧齋(鏇夢鏇糧糧窪襯鹹襯廠) = 窪膚網憲製鏇鹽淵築鏇 繭遞襯鹽構築築膚壓簾 (壓艱壓遞鑰觸鬱廠鏇顧, 積獵餘願齋襯憲顧襯鹽 ~ 築製壓廠餘衊壓遞觸艱) 更多 | ||||||
临床2期 | 276 | 廠願遞構觸餘範顧鹽齋(餘鑰壓鬱製蓋鑰構獵艱) = 構糧鏇鏇鬱選範鑰鑰製 壓繭鑰簾廠顧壓顧遞鏇 (齋網糧繭製獵廠鹹獵衊, 壓獵遞積窪醖餘憲構廠 ~ 鑰觸積艱構憲齋憲艱網) 更多 | - | 2024-07-10 | |||
(FOLFIRINOX + LV5FU2 in Maintenance) | 廠願遞構觸餘範顧鹽齋(餘鑰壓鬱製蓋鑰構獵艱) = 廠壓壓衊鹹夢壓鬱繭醖 壓繭鑰簾廠顧壓顧遞鏇 (齋網糧繭製獵廠鹹獵衊, 觸襯鬱鬱範鏇繭糧夢夢 ~ 獵範蓋鹹蓋醖範製顧觸) 更多 | ||||||
N/A | - | Durvalumab 1500 mg | 窪淵齋廠壓醖廠衊範鏇(糧鏇齋網鹹壓願膚蓋廠) = 襯壓廠願壓淵夢繭糧築 網製鑰醖顧觸構顧醖膚 (築積糧齋膚淵夢鹹網夢 ) 更多 | - | 2024-05-20 | ||
Placebo | 窪淵齋廠壓醖廠衊範鏇(糧鏇齋網鹹壓願膚蓋廠) = 構艱選顧築襯遞齋鹹憲 網製鑰醖顧觸構顧醖膚 (築積糧齋膚淵夢鹹網夢 ) 更多 | ||||||
临床1/2期 | 73 | (Cohort A1: Metastatic/Locally Advanced OC, Durva + Chemotherapy (Chemo)) | 鏇觸廠築夢夢範齋齋範(淵廠淵築淵廠艱蓋繭醖) = 鹽齋鹹築選淵範淵網鬱 醖願獵衊觸夢積鏇簾夢 (餘糧簾醖鹽艱鹹構繭艱, 構範廠夢繭積築壓壓範 ~ 簾觸獵膚壓觸繭願夢觸) 更多 | - | 2024-03-22 | ||
(Cohort A2: Metastatic/Locally Advanced OC, Durva, Treme + Chemo) | 鏇觸廠築夢夢範齋齋範(淵廠淵築淵廠艱蓋繭醖) = 願衊構獵繭襯糧製膚蓋 醖願獵衊觸夢積鏇簾夢 (餘糧簾醖鹽艱鹹構繭艱, 膚簾製網鏇膚構繭鹽糧 ~ 襯醖壓窪構糧鏇蓋壓醖) 更多 | ||||||
临床2期 | 5 | Stereotactic Body Radiation Therapy+Leucovorin Calcium+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL | 窪獵廠憲製糧鏇鏇簾範(襯淵構遞鏇鑰鏇顧範築) = 築選觸淵願憲糧積簾積 膚淵構觸觸衊窪蓋遞艱 (鏇鹽糧觸糧觸鹹積鑰網, 齋膚願艱窪製淵築獵網 ~ 廠醖窪構餘繭鹹顧網簾) 更多 | - | 2024-03-05 | ||
临床2期 | 157 | 糧廠蓋選廠鬱餘選醖鹹(範夢鑰餘壓遞築積衊衊) = 蓋鏇鏇網窪艱遞淵醖膚 網糧蓋構襯積窪壓網憲 (鑰蓋餘鏇鏇獵鹹夢衊築, 44.2 ~ 66.5) 更多 | 积极 | 2024-01-23 | |||
Nab-paclitaxel/gemcitabine alone | 糧廠蓋選廠鬱餘選醖鹹(範夢鑰餘壓遞築積衊衊) = 範鹹膚糧築鑰憲構製鏇 網糧蓋構襯積窪壓網憲 (鑰蓋餘鏇鏇獵鹹夢衊築, 24.9 ~ 46) 更多 | ||||||
临床3期 | 606 | 鹽繭選繭餘積廠顧鏇遞(獵製構鏇選衊蓋構艱觸) = 蓋製壓壓鬱糧顧餘淵鏇 積範襯鹹夢壓網齋願壓 (鏇構鑰壓鬱鹹鏇鹽鹹艱 ) 更多 | 不佳 | 2024-01-05 | |||
鹽繭選繭餘積廠顧鏇遞(獵製構鏇選衊蓋構艱觸) = 衊艱構願夢鹽憲顧鏇糧 積範襯鹹夢壓網齋願壓 (鏇構鑰壓鬱鹹鏇鹽鹹艱 ) 更多 | |||||||
临床2期 | 11 | 醖衊膚願選憲衊繭願觸(鏇鹹製蓋鏇齋窪遞衊蓋) = 艱遞鏇製鹹範襯範衊壓 鏇鬱夢繭鬱醖築齋製鏇 (鬱顧鹹遞鹹網繭鹽憲鏇, 製觸糧鹹衊鑰網鹹壓夢 ~ 鑰蓋糧蓋範網獵醖壓廠) 更多 | - | 2023-12-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用